Does ACRS pay a dividend and is it safe?

Aclaris Therapeutics Inc. (ACRS) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / ACRS / dividends

CLYM (28) IRWD (59) GERN (28) NVCT (37) ⌘ Pro Terminal →

Aclaris Therapeutics Inc. (ACRS) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is ACRS trading relative to its 50-day, 200-day, and 52-week technical levels?

ACRS last traded at $3.80 (-4.28% on volume of 1,644,677 shares), positioning the stock -20.67% below its 50-day simple moving average ($4.79) and -16.48% below its 200-day simple moving average ($4.55). Across its 52-week range of $2.10 to $6.60, ACRS sits at the 37.8% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.33 to $4.27).

$3.80 -4.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.76

Aclaris Therapeutics Inc. (ACRS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $584.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACRS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Aclaris Therapeutics Inc. (NASDAQ: ACRS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $3.80 (-4.28% 1D, market cap $584.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ACRS ranks #991 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACRS compare to CLYM and IRWD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACRS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 73.3%, and ROIC of -35.0%. By comparison, CLYM (Climb Bio Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $588.7M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C- grade (59/100 RQD, P/E 24.9x, ROIC 85.0%, cap $578.3M). Among the 5-stock peer group, IRWD leads on earnings multiple (24.9x) while IRWD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACRS?

▼

Per ACRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001557746), Aclaris Therapeutics Inc. generated $7.8M in revenue (-58.2% YoY), -$64.9M in net income, and -$47.2M in free cash flow against $160.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.76 (-0.96%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-17.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACRS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (19/100 Composite)

🔍 WHY ACRS SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+6/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (26% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.47+8.6% Next Q

Q2 (-2Q)

Grade E$3.77+0.5% Next Q

Q3 (-1Q)

Grade E$3.79+0.3% Next Q

Current

Grade E$3.80-12% Hist 90D α

Trajectory: E (15) → E (19)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACRS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACRS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.79) and Max Pain ($3.99) forces dealer call-delta covering toward $6.93.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACRS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACRS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 19%NO 81%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACRS)

✓Walkthrough of ACRS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACRS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.11%📐 HORIZONTAL RANGE

2026-11-03O $3.99H $3.99L $3.80C $3.80VOL 1.88M

RES: $8.04SUP: $2.99SMA50: $4.79SMA200: $4.55

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACRS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACRS Butterfly Map → + Track ACRS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -58.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ACRS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACRS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACRS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACRS)

Health Care Rank #991 of 1015 ⚔️ CLYM vs ACRS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACRS vs. CLYM, IRWD, GERN, NVCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Aclaris Therapeutics Inc. (ACRS) ranks #991 by composite RQD confidence (19/100, grade E) and #418 by equity capitalization ($584.4M). Within this direct 5-issuer industry benchmark cohort, IRWD leads on earnings valuation at 24.9x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with ACRS at 19/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACRS ACTIVE Aclaris Therapeutics Inc.	E	19/100	—	73.3%	-35.0%	-4.28%	$584.4M	Benchmark Subject
CLYM Climb Bio Inc.	E	28/100	—	—	-35.0%	-4.98%	$588.7M	/clym-vs-acrs →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C-	59/100	24.9x	—	85.0%	-1.14%	$578.3M	/irwd-vs-acrs →
GERN Geron Corporation	E	28/100	—	—	-20.2%	+3.88%	$574.6M	/gern-vs-acrs →
NVCT Nuvectis Pharma Inc.	D-	37/100	—	—	-35.0%	+3.79%	$602.7M	/nvct-vs-acrs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001557746 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aclaris Therapeutics Inc. (ACRS) reported GAAP revenue of $7.8M (-58.2% vs. FY2024 revenue of $18.7M , and -75.0% cumulative change since FY2023) , GAAP net income of -$64.9M, operating cash flow of -$47.1M, and free cash flow of -$47.2M (-133.8% YoY). On the balance sheet, ACRS closed FY2025 with $160.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.8M	-$64.9M	-$47.1M	-$47.2M	$160.5M	—
FY2024 (FY)	2024-12-31	$18.7M	-$132.1M	-$20.1M	-$20.2M	$220.3M	—
FY2023 (FY)	2023-12-31	$31.2M	-$88.5M	-$78.3M	-$78.3M	—	—

3. ACRS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ACRS compare to CLYM and IRWD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ACRS?

Where is ACRS trading relative to its 50-day, 200-day, and 52-week technical levels?

ACRS last traded at $3.80 (-4.28% on volume of 1,644,677 shares), positioning the stock -20.67% below its 50-day simple moving average ($4.79) and -16.48% below its 200-day simple moving average ($4.55). Across its 52-week range of $2.10 to $6.60, ACRS sits at the 37.8% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.33 to $4.27).

Direct Sub-Reports: ACRS RQD Cockpit ACRS 12M Forecast ACRS Earnings & Move ACRS Dividends & DRIP ACRS Insiders & 13F ACRS Whale Options ACRS Profit Sankey ACRS News & Why

ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ SEC XBRL & RQD VERIFIED

ACRS — Aclaris Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Aclaris Therapeutics Inc. (ACRS) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.80 (-4.28% 1D, market capitalization $584.4M).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 73.3%, operating margin of -60.0%, and free cash flow yield of -8.04%.
Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Aclaris Therapeutics Inc. (ACRS) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations,. The profile does not describe its products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Aclaris Therapeutics Inc. (ACRS) reported $7.8M in annual revenue (up from $18.7M in FY2024, -58.2% YoY) and -$64.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($31.2M revenue, -$88.5M net income) through FY2025, ACRS scaled operating cash flow to -$47.1M and free cash flow to -$47.2M, backed by $160.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 19/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.04% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $2.10 – $6.60 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ACRS carries a macro regime beta of 1.00 and gross margin of 73.3%.

Key Question #1: Can ACRS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $7.8M and free cash flow of -$47.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ACRS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ACRS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aclaris Therapeutics Inc. (ACRS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACRS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Yahoo Finance report covering Aclaris Therapeutics Inc. (ACRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (ACRS), Globus Medical (GMED) and Johnson & Johnson (JNJ)

The Globe and Mail report covering Aclaris Therapeutics Inc. (ACRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma - Slideshow (NASDAQ:ACRS) 2026-10-29

Seeking Alpha report covering Aclaris Therapeutics Inc. (ACRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Wedbush maintains Outperform rating on Aclaris Therapeutics, $8 price target

TradingView report covering Aclaris Therapeutics Inc. (ACRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

Yahoo Finance report covering Aclaris Therapeutics Inc. (ACRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

Aclaris Therapeutics Prices $50 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Quiver Quantitative report covering Aclaris Therapeutics Inc. (ACRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug

Benzinga report covering Aclaris Therapeutics Inc. (ACRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Aclaris Therapeutics, Inc. (ACRS) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Aclaris Therapeutics Inc. (ACRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACRS Bull vs. Bear Conversation Board — What's Your Call at $3.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACRS 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $4.88 (+22.9%)

📌 Pinned Debate

Wedbush maintains an Outperform rating with an $8 price target, roughly double the $3.99 price.

The street is overcomplicating Aclaris Therapeutics Inc. (ACRS). Wedbush maintains an Outperform rating with an $8 price target, roughly double the $3.99 price.. With an RQD score of 19/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $4.29.

EarningsSniper 🐂 BULL

Both sides have a point here — ACRS's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $3.10 (-21.9%)

Spot @ $3.97

Operating margin of -60% and Altman Z of 0.2 show persistent losses and balance-sheet distress alongside a $50.0 Million equity offerin

I respect the product at Aclaris Therapeutics Inc., but the stock at $3.97 is a different story. Operating margin of -60% and Altman Z of 0.2 show persistent losses and balance-sheet distress alongside a $50.0 Million equity offering.. FCF yield is -8.04% and RQD sits at 19/100 (E) — why pay up here when you can wait for next quarter's numbers?